Cell-Free DNA Chromatin Immunoprecipitation (ChIP) for Diagnosing Cancer
ConditionCancer of Pancreas
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity of Central Florida
About this trial
The goal of this research is to use chromatin immunoprecipitation, a method used to study protein-DNA interaction, as a tool to diagnose and prognose pancreatic ductal adenocarcinoma in human samples.
This is a Non-Human Subject Research study. All participants are de-identified.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
18 years old or older
Pancreatic cancer patients
Disqualifiers
Children may not register
Persons who are unable to consent may not register
Trial population
The investigators want to control for approximate age and have two participants of each gender, and are looking to get 4 without Pancreatic Ductal Adenocarcinoma (PDAC), and 4 of each stage of PDAC (1 through 4).
Trial design
Design model
Other
Time perspective
Other
Treatments tested in this trial
Non-Human Subject Research study.
Other interventionThis is a Non-Human Subject Research study. There is no intervention. All participants are de-identified.
Treatment groups
24 Participants
are divided into 1 treatment groupGroup A: Pancreatic Ductal Adenocarcinoma1 intervention
Trial outcomes
Primary outcomes
1
Level of c-ERBB1 in blood using Chromatin immunoprecipitation and Reverse transcription-quantitative polymerase chain reaction
Chromatin immunoprecipitation is a method used to study the interaction between DNA and proteins. This makes it a valuable tool for detecting disease state in samples as it allows us to study gene regulation. To put this into practice, DNA is crosslinked to proteins and precipitated out of solution using an antibody. In this case, anti-H3K36me3 was used as it is a marker for active gene regulation which allows for separation of actively transcribed genes. This is synonymous to selecting for a certain disease state that is ongoing. Once this is done, Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) is run on the sample to select for EGFR c-ERBB1, which is an epithelial growth factor (EGFR) mutation which is present in 93% of PDAC cases. Analysis of relative levels of c-ERBB1 should allow for us to diagnose and prognose different stages of PDAC.
Time frame
1 yearSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov